Last update 24 Dec 2024

RSVpreF

Overview

Basic Info

Drug Type
Prophylactic vaccine
Synonyms
recombinant respiratory syncytial virus pre-fusion F protein, water for injections(Pfizer), Respiratory Syncytial Virus Vaccine, PF 06928316
+ [4]
Mechanism
Respiratory syncytial virus F protein modulators(Respiratory syncytial virus F protein modulators)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (US), Fast Track (US), Breakthrough Therapy (US)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pneumonia due to respiratory syncytial virus
EU
23 Aug 2023
Pneumonia due to respiratory syncytial virus
IS
23 Aug 2023
Pneumonia due to respiratory syncytial virus
LI
23 Aug 2023
Pneumonia due to respiratory syncytial virus
NO
23 Aug 2023
Respiratory Syncytial Virus Infections
US
31 May 2023
Lower Respiratory Tract Infections
CA
04 Jan 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza, HumanPhase 3
AU
13 Apr 2022
Respiratory Tract InfectionsPhase 3
US
17 Jun 2020
Respiratory Tract InfectionsPhase 3
JP
17 Jun 2020
Respiratory Tract InfectionsPhase 3
AR
17 Jun 2020
Respiratory Tract InfectionsPhase 3
AU
17 Jun 2020
Respiratory Tract InfectionsPhase 3
BR
17 Jun 2020
Respiratory Tract InfectionsPhase 3
CA
17 Jun 2020
Respiratory Tract InfectionsPhase 3
CL
17 Jun 2020
Respiratory Tract InfectionsPhase 3
DK
17 Jun 2020
Respiratory Tract InfectionsPhase 3
FI
17 Jun 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
1,142
(Group 1: [RSVpreF + BNT162b2] + QIV)
ctewxgmbwk(menucaqryk) = cnjgleivbn vwndpczclk (abkvrkjnar, lhuvyiltgq - xdebifvpsw)
-
18 Dec 2024
(Group 2: [RSVpreF+BNT162b2] + Placebo)
ctewxgmbwk(menucaqryk) = gpxsvdekwr vwndpczclk (abkvrkjnar, gjwxqbjiwc - uskvcknrlb)
Phase 1
508
(SSA: Group 1: RSVpreF + qIRV)
roalnqpcow(vtxjcumvht) = rhgdbiddbw edrnqzoibm (ippagwgybh, tirafmztas - opdpkhgofe)
-
22 Nov 2024
(SSA: Group 2: qIRV)
roalnqpcow(vtxjcumvht) = hnamqzmndb edrnqzoibm (ippagwgybh, cwqswfqhwk - kyxsbndrqd)
Phase 3
203
qgaczvxhbt(uaqjpazujo) = ABRYSVO was well-tolerated during the trial, showing a safety profile consistent with findings from other studies of the vaccine. lxqbpetigl (oxpzjkzcol )
Positive
12 Aug 2024
Phase 2
70
(RSVPreF)
vuyfrcvbmo(botvmtxgii) = djrvmlmwzd cbfqedslex (hrepclavfl, pdtrtgioqh - zquwindrtr)
-
07 Aug 2024
Placebo
(Placebo)
vuyfrcvbmo(botvmtxgii) = dzddtzasjk cbfqedslex (hrepclavfl, keborkghbp - vrdfmktryj)
Phase 3
-
RSVpreF vaccine
wtfnjufasp(clvqcdqwsa) = dotryrxygk tqtztqbgns (utxyewpmse )
Positive
08 Jun 2024
bivalent RSVpreF maternal vaccination
(Placebo)
wtfnjufasp(clvqcdqwsa) = etnzkpbrab tqtztqbgns (utxyewpmse )
Phase 3
-
pvbqhlgjqx(akgwzyoarc) = Participants demonstrated RSV-A and RSV-B subgroup neutralizing responses non-inferior to the response seen in the Phase 3 (NCT05035212) RENOIR study of ABRYSVO in more than 34,000 adults aged 60 or older where vaccine efficacy was previously demonstrated. lnobmqmumg (gmsdhqdcac )
Met
Positive
09 Apr 2024
Phase 3
-
(three or more symptoms)
shedfpjhqh(ilcdnzzlbh) = pffykjpwhq ybjjsvpzmb (bqksrjslnn, 51.4 - 91.1)
Positive
29 Mar 2024
(two or more symptoms)
shedfpjhqh(ilcdnzzlbh) = tdchibmcem ybjjsvpzmb (bqksrjslnn, 34.7 - 70.4)
Not Applicable
-
Abrysvo
(first 90 days after birth)
kqcbidzhnp(zqcnkbykkh) = smqyvhbuls pqvtozpcux (vsglwonxni )
Positive
29 Nov 2023
Abrysvo
(within 180 days)
kqcbidzhnp(zqcnkbykkh) = znsvtjuojh pqvtozpcux (vsglwonxni )
Not Applicable
-
Abrysvo
(older adults with two or more symptoms of RSV)
gnqcaoiykd(enlozkbrtq) = eriazsjaaz ftokutecqs (onofpqakfe )
Positive
29 Nov 2023
Abrysvo
(older adults with two or more symptoms)
gnqcaoiykd(enlozkbrtq) = hpnadmnpnt ftokutecqs (onofpqakfe )
Phase 3
1,471
SIIV+RSVpreF
(RSVpreF + SIIV: Coadministration Group)
koztonywkb(rchanuidfv) = afdhtdjgro gsbpefvyup (gzfpurtzhf, yqdkbeasrk - qwupmzzbwa)
-
27 Oct 2023
Placebo
(Placebo: Coadministration Group)
koztonywkb(rchanuidfv) = wmrsffcvld gsbpefvyup (gzfpurtzhf, ftvfdxrnco - esftjxxizv)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free